Thieme E-Books & E-Journals - Pneumologie / Issue

P 57

Uhlenbruch, M; Krüger, S: Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non small cell lung cancer

Abstract
HTML

P 92

Fannana, A; Yilamz, S; Escherich, F; Thiede, S; Atug, E; Wiest, G; Beister, T: Schweres ARDS bei Erstdiagnose Lungenmanifestation eines diffus großzelligen B-Zell-Lymphom

Abstract
HTML

P 229

Thomas, M; Spigel, D; Korbenfeld, E; Hayashi, H; Corre, R; Cho, B; Psyrri, A; Cobo Dols, M; Parkhomenko, E; Baxter, D; Patel, N; Trinchese, F; Diaz-Padilla, I; Reck, M: Interim Analysis of GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients (pts) With Previously Untreated Locally Advanced/Metastatic (LA/M) PD-L1 High (TPS>/=50%) Non-Small Cell Lung Cancer (NSCLC)

Abstract
HTML

FV 246

Paulus, G; Tufman, A; Behr, J; Resuli, B; Kauffmann-Guerrero, D: Strukturierte prospektive Patientenbefragung zum Krankheits- und Therapieverständnis von Patienten mit Lungenkarzinom

Abstract
HTML

P 291

Resuli, B; Walter, J; Kauffmann-Guerrero, D; Mertsch, P; Arredondo, M; Arnold, P; Schneider, C; Behr, J; Tufman, A: Toxicity profile and efficacy of docetaxel following paclitaxel-or pemetrexed-platinum chemotherapy alone or in ccombination with immune checkpoint inhibitors in NSCLC patients: A single Institution experience

Abstract
HTML

P 294

Ruiter, G; Tu, H; Ahn, M; Yoh, K; Zugazagoitia, J; Smit, E; Wu, Y; Planchard, D; Cho, B; Wehler, B; Zhao, Y; Wehler, T; von Wangenheim, U; Rohrbacher, M; Sadrolhefazi, B; Lin, G; Yu, Y; Nadal, E; Heymach, J: Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC

Abstract
HTML

P 303

Opdam, F; Heymach, J; Berz, D; Minal, B; Tu, H; Wu, Y; Ruiter, G; Ahn, M; Zugazagoitia, J; Smit, E; Planchard, D; Cho, B; Wehler, B; Zhao, Y; Lin, G; Yu, Y; Nadal, E; Wehler, T; Rohrbacher, M; Schroeter, L; Serra, J; Sadrolhefazi, B; Yoh, K; Yamamoto, N: Zongertinib (BI 1810631) for HER2-positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial

Abstract
HTML

P 310

Resuli, B; Völter, F; Walter, J; Arredondo, M; Behr, J; Dahlmann, P; Hirner, R; Kauffmann-Guerrero, D; Mertsch, P; Schneider, C; Tufman, A: Correlation between inflammatory markers and quantitative imaging biomrakers in pretreatment 18F-FDg PET/CT in NSCLC patients treated with first-line immune checkpoint inhibitors

Abstract
HTML

FV 316

Webendörfer, M; Oezkan, F; Winantea, J; Wiesweg, M; Metzenmacher, M; Theegarten, D; Darwiche, K; Bölükbas, S; Doerr, F; Taube, C; Stuschke, M; Opitz, M; Schuler, M; Eberhardt, W: Lungenkrebs bei jungen Erwachsenen ist assoziiert mit fortgeschrittenem Tumorstadium bei Erstdiagnose und erhöhter Frequenz therapeutisch adressierbarer Mutationen

Abstract
HTML

P 317

Sadeghi, D; Wesseler, C; Weisser, W; Wiest, G; Atug, E: Fallbericht eines metastasierten kleinzellig-neuroendokrinen Karzinoms (SCLC) mit denovo L858R-EGFR-Mutation einer jungen Nichtraucherin

Abstract
HTML

P 323

Wermke, M; Saalfeld, F; Gambardella, V; Kuboki, Y; Olatunji, A; Morgensztern, D; Sayehli, C; Sanmamed, M Miguel F.; Arriola, E; Wolf, J; Liza Villaruz, L; Studeny, M; Bouzaggou, M; Fang, X; Felip, E: Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC

Abstract
HTML

FV 326

Riese, J; Seillier, L; Kühnel, M; Länger, F: Analysis of master regulatory transcription factors and their associated transcriptomic profiles in SCLC patients

Abstract
HTML

P 333

Wiesweg, M; Gadgeel, S; Cho, B; Lu, S; Felip, E; Hayashi, H; Spira, A; Besse, B; Thomas, M; Owen, S; Kim, Y; Lee, S; Mourao, J; Lee, Y; Zhao, Y; Fang, Y; Girard, N; Liu, Z; Sun, P; Cunha Souza Oliveira, S; Shen, H; Paz-Ares, L; Matsumoto, S; Tanaka, H; Ahmad, A; Andabekov, T; Sunpaweravong, P; Özyilkan, Ö; Yang, J; Gottfried, M; Hernandez, O; Kimmich, M; Cortinovis, D; Kaen, D; García Montes, L; Popat, S; Newsom-Davis, T; Spigel, D; Xie, J; Sun, T; Fennema, E; Daksh, M; Ennis, M; Sethi, S; Bauml, J; Nguyen, D: Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

Abstract
HTML

FV 346

Stoleriu, C; Beutel, T; Gesierich, W; Reinmuth, N; Hatz, R; Stoleriu, M: Akzeptanz telemedizinischer Anwendungen bei Patienten mit Lungenkarzinom: Eine komparative Analyse in der Onkologie und onkologischen Thoraxchirurgie

Abstract
HTML

P 357

Negrao, M; Arbour, K; Burns, T; Cappuzzo, F; Dingemans, A; Girard, N; Henning Grønberg, B; Hochmair, M; Leal, T; Lindsay, C; Lu, S; Nishio, M; Paz-Ares, L; Reck, M; Sabari, J; William, W; Chen, A; Visseren-Grul, C; Peters, S; Thomas, M: SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12 C-mutant advanced NSCLC (Trial in Progress)

Abstract
HTML

P 366

Goldman, J; Sands, J; Hallqvist, A; Kim, H; Li, G; Wu, L; Su, W; Bayt, T; Yang, X; Hochmair, M; Grohé, C: LIBRETTO-432 Trial in Progress: A Phase 3 study of adjuvant selpercatinib or placebo in Stage IB-IIIA Ret fusion-positive (RET+) NSCLC

Abstract
HTML

P 369

Nakagawa, K; Garon, E; Nishio, M; Seto, T; Nishio, K; Kasahara, K; Nishino, K; Satouchi, M; Yoh, K; Hayashi, H; Enatsu, S; Frimodt-Moller, B; Matsui, T; Chacko Varughese, S; Visseren-Grul, C; Reck, M; Hammerschmidt, S: RELAY: Final Overall Survival with Erlotinib+Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC (mNSCLC)

Abstract
HTML

P 375

Fujiwara, Y; Ammakkanavar, N; Hollebecque, A; Goroff, Y; Lee, D; Burns, T; Cassier, P; Youn Han, J; Italiano, A; Koyama, T; Yong Shim, B; Heist, R; Sabari, J; Spira, A; Bodor, J; Chu, Q; Durm, G; Singhal, N; Chisamore, M; Fink, A; Willard, M; Oxnard, G; Dragnev, K; Thomas, M: Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC

Abstract
HTML

P 379

Zhou, C; Novello, S; Garrido Lopez, P; Dooms, C; Alatorre-Alexander, J; Reinmuth, N; Gilligan, A; Payakachat, N; Cocks, K; Worthy, G; Goto, K: Health-related Quality of Life (HRQoL) and Symptoms in LIBRETTO-431 Patients with RET Fusion-positive Advanced Non-Small-Cell Lung Cancer (NSCLC)

Abstract
HTML

P 382

Perol, M; Solomon, B; Goto, K; Park, K; Nadal, E; Bria, E; Martin, C; Bar, J; Williams, J; Puri, T; Li, J; Lin, B; Zhou, C; Schumann, C: The Intracranial Outcomes of 1L Selpercatinib in Advance RET Fusion positive (RET+) NSCLC: LIBRETTO-431 Study

Abstract
HTML

FV 423

Schulz, C; Swart, S; Bernhardt, D; Safi, S; Fuchs, F; Hildner, K; Tufman, A; Reinmuth, N; Hackanson, B; Raab, S; Kern, J; Jung, P; Heudobler, D: NSCLC mit synchroner Oligometastasierung zum Zeitpunkt Erstdiagnose. Einfluss unterschiedlicher Systemtherapien auf die Prognose. Eine BZKF-Analyse.

Abstract
HTML

P 442

Ferrara, D; Abenavoli, E; Beyer, T; Grünert, S; Hacker, M; Hesse, S; Hofmann, L; Rullmann, M; Sabri, O; Sciagra, R; Shiyam Sundar, L; Tönjes, A; Wirtz, H; Yu, J; Frille, A: Detection of cancer-associated cachexia in lung cancer patients using whole-body [18F]FDG-PET/CT imaging: A multi-center study

Abstract
HTML

P 445

Tischler, A; Taube, C; Darwiche, K; Winantea, J; Bonella, F; Opitz, M; Zellerhoff, H; Eberhardt, W; Wiesweg, M; Theegarten, D; Metzenmacher, M; Tazeoglu, H; Oezkan, F: Diffuse Lungenparenchymerkrankung nach Immuntherapie, Tyrosinkinaseinhibitoren und Antikörper-Wirkstoff-Konjugaten

Abstract
HTML

P 450

Frille, A; Stiller, M; Wald, A; Seyfarth, H; Metze, M; Platz, M; Krücken, I; Boeschen, M; Bläker, H; Wirtz, H; von Laffert, M: Comparative cell-free mutation analysis for the diagnosis of malignant pleural effusion in lung cancer patients: The Liquid Pleura Project

Abstract
HTML

FV 453

Huber, R; Cavic, M; Balata, H; Borondy Kitts, A; Field, J; Henschke, C; Kazerooni, E; Kerpel-Fronius, A; Smith, R; Taioli, E; Ventura, L; Lam, S; Yankelevitz, D; Tammemägi, M: Früherkennung und Screening des Lungenkarzinoms – Empfehlungen der IASLC-Expertengruppe

Abstract
HTML

P 513

Lange, V; Hillejan, L; Barani, M: Zentraler inflammatorischer Pseudotumor des distalen linken Hauptbronchus: Therapie durch parenchymerhaltende isolierte Bronchusresektion

Abstract
HTML

P 517

Dobrowolski, E; Groß, T; Zender, L: Fallbericht zur diagnostischen Differenzierung einer aktiven Tuberkulose von einem Tumorprogress bei MET-amplifiziertem NSCLC unter Crizotinib-Therapie.

Abstract
HTML

P 521

Demirtürk, M; Völkel, N; Bootsveld, A; Mahnken, A; N'Guessan, P: Fallbericht: Hämostase eines blutenden Bronchialkarzinoms mit erfolgreicher Embolisation der linken Bronchialarterie

Abstract
HTML

P 537

Wiewrodt, R; Berber, A; Wehde, D; Schulte, S; Krüger, V; Reichelt, J; Dickgreber, N; Fischer, S: Palliative anatomische Resektionen zur Herstellung der Therapiefähigkeit bei metastasierten Lungenkarzinomen

Abstract
HTML

P 544

Schulz, C; Swart, S; Bernhardt, D; Safi, S; Fuchs, F; Hildner, K; Kern, J; Jung, P; Tufman, A; Reinmuth, N; Hackanson, B; Raab, S; Heudobler, D: NSCLC mit synchroner Oligometastasierung zum Zeitpunkt Erstdiagnose. Einfluss von System- und Lokaltherapie auf die Prognose. Eine BZKF-Analyse

Abstract
HTML

P 547

Liebers, U; Bieneck, F; Zaatar, M; Darb-Esfahani, S; Grohé, C: Casus einer kompletten pathologischen Remission nach zielgerichteter Tumortherapie – Wie gelingt die Individualisierung der Systemtherapie im kurativen Setting ?

Abstract
HTML

Subscribe to RSS

Pneumologie